| Company/Division name | StemCultures |
| Type of work | Manufacturing |
| Reshoring category: | Kept from Offshoring |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | China |
| City reshored to: | Rensselaer |
| State(s) reshored to: | NY |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell growth factors |
| What non-domestic negative factors made offshoring less attractive? | Intellectual property risk |
| What domestic positive factors made reshoring more attractive? | Government Incentives |
